News

Stefan Oschmann, president of emerging markets at Merck, said that the company’s endeavors of this proposed expansion will lead to increase in sales in the region by 30%,

Nanotechnologies have been proven as a valuable adjunct to the development of new therapeutics. Nanoparticles provide a much larger surface area thereby increasing the dissolution rate resulting in

The technology allows a single in-office minimally invasive surgical procedure. The patent also allows the device to deliver medication or therapeutic agents to the uterine cavity. ContraMed has

Reportedly, the entreprise value of Merial has been fixed at $8bn and the entreprise value of Intervet/Schering-Plough at $8.5bn, leading to a true-up payment of $250m to Merck

The team said that their work could help to reduce the possibility and risk of infections amongst newborn babies, along with the development of new and suitable treatments.

FreeSlate claimed that it provides researchers with increased experimental capacity and faster decision-making via its microscale, high-throughput technology, lab execution and analysis software, and experienced engineers and application

PharPoint plans to utilise Medrio’s technology in all phases of clinical drug development from Phase I – IIIb studies as well as post marketing studies, registries and outcomes

According to Neil Ferguson, vice-president of finance with Stirling Products in Charlottetown, Stirling Products of Australia will have control over both the North Sydney plant and the Charlottetown

UK-based BP is a manufacturer of self adhesive labels for the pharmaceutical, healthcare, cosmetic and food & drink markets, often providing them as part of an authentication solution.